These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7761669)

  • 1. Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients.
    Buemi M; Allegra A; Laganà A; Aloisi C; Privitera M; Morabito N; Frisina N
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):195-7. PubMed ID: 7761669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does anemia correction by rHuEPO improve uremic cardiopathy?
    Carletti P; Bibiano L; Boggi R; Taruscia D; Mioli V
    Kidney Int Suppl; 1993 Jun; 41():S70-1. PubMed ID: 8320949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
    Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ
    Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy.
    Massa E; Madeddu C; Lusso MR; Gramignano G; Mantovani G
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):175-82. PubMed ID: 16213740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of recombinant human erythropoietin (rh-EPO) in the treatment of anemia in hemodialysis patients: a multicenter Italian experience.
    Buccianti G; Colombi L; Battistel V
    Haematologica; 1993; 78(2):111-7. PubMed ID: 8349186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin.
    Bárány P; Pettersson E; Konarski-Svensson JK
    Nephrol Dial Transplant; 1993; 8(5):426-32. PubMed ID: 8393547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of treating predialysis patients with recombinant human erythropoietin.
    Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
    Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin treatment of idiopathic myelofibrosis.
    Aloe Spiriti M; Latagliata R; Avvisati G; Battistel V; Montefusco E; Spadea A; Petti MC
    Haematologica; 1993; 78(6):371-3. PubMed ID: 8175031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of correcting anemia with recombinant erythropoietin on the central hemodynamic indices of patients on regular hemodialysis].
    Ermolenko VM; Khvoĭnitskiĭ VA; Suprun EK; Tsukerman LI; Pokrovskiĭ IuA
    Ter Arkh; 1992; 64(7):86-8. PubMed ID: 1440377
    [No Abstract]   [Full Text] [Related]  

  • 14. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 16. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
    Sikole A; Spasovski G; Zafirov D; Polenakovic M
    Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of rHuEPO in treatment of uremic anemia prior to end-stage renal disease.
    Koene RA; Frenken LA
    Kidney Int Suppl; 1992 Oct; 38():S142-7. PubMed ID: 1405365
    [No Abstract]   [Full Text] [Related]  

  • 19. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
    Raja R; Bloom E; Johnson R; Goldstein M
    Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin].
    Marusza W; Matuszkiewicz-Rowińska J; Tomik Z; Andrzejewski A; Rokicka M; Paszkowska M; Drygieniec D; Bobilewicz D; Zawadzka M; Abbas-Fatah A
    Pol Tyg Lek; 1995 Oct; 50(40-44):15-8, 31. PubMed ID: 8650050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.